Over a year since this announcement hit the asx and still we wait for the peer review process. In that time, both Prof Sverdlov's and Prof Ngo's standing seems to have risen as well as an increase in the conversations around cardio-oncology and the need for therapies that consider both treatment for cancer and care for the heart.
Hopefully this paper lands soon and heralds new interest in bisantrene and RAC. Was there any mention of this research during the recent investor sessions?
Over a year since this announcement hit the asx and still we...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
